Methods of extracting RNA

Abstract

Methods and materials are disclosed for rapid and simple extraction and isolation of RNA from a biological sample involving the use of an acidic solution and a solid phase binding material that has the ability to liberate nucleic acids from biological samples, including whole blood, without first performing any preliminary lysis to disrupt cells or viruses. No detergents or chaotropic substances for lysing cells or viruses are needed or used. Viral, bacterial and mammalian genomic RNA can be isolated using the method of the invention. RNA isolated by the present method is suitable for use in downstream processes such as RT-PCR.

Description

Claims

1. A method for extracting ribonucleic acid from a biological sample containing at least one of cells or viruses comprising: a) contacting the sample with an acidic solution to form a mixture;b) combining the mixture with a solid phase binding material selected to have the ability to liberate ribonucleic acid directly from biological samples without first performing any preliminary lysis, and wherein no chaotropic agents or detergents are used to effect lysis, and whereby the solid phase binding material causes lysis of cells and viruses to liberate ribonucleic acid; andc) binding ribonucleic acid on the solid phase.

2. The method of claim 1 further comprising: d) separating the sample from the solid phase having ribonucleic acid bound theretoe) optionally washing the solid phase with at least one wash solution; andf) eluting the bound ribonucleic acid from the solid phase by contacting the solid phase material with a reagent to release the bound RNA into solution.

3. The method of claim 1 wherein the step of forming the mixture of the sample and the acidic solution is concurrent with the step of combining the mixture with the solid phase.

4. The method of claim 1 wherein the mixture of the sample and the acidic solution is formed before the step of combining the mixture with the solid phase.

5. The method of claim 1 wherein the solid phase is selected from particles, microparticles, fibers, beads, membranes, test tubes and microwells.

6. The method of claim 1 wherein the solid phase comprises a matrix portion and a nucleic acid binding portion.

7. The method of claim 6 wherein the matrix portion is selected from silica, glass, insoluble synthetic polymers, insoluble polysaccharides, metals, metal oxides, and metal sulfides.

8. The method of claim 6 wherein the matrix portion is selected from magnetically responsive materials coated with silica, glass, synthetic polymers, or insoluble polysaccharides.

9. The method of claim 1 wherein the solid phase comprises microparticles having a diameter of less than 10 μm.

10. The method of claim 9 wherein the microparticles are magnetically responsive.

11. The method of claim 9 wherein mixtures of more than one size of particles are used.

12. The method of claim 11 wherein particles of at least one size have a nucleic acid binding portion and particles of at least one other size do not have a nucleic acid binding portion.

13. The method of claim 6 wherein the solid phase material further comprises a covalently linked nucleic acid binding portion which permits capture and binding of ribonucleic acids.

14. The method of claim 1 wherein the solid phase materials further comprise a non-covalently associated nucleic acid binding portion which permits capture and binding of ribonucleic acids.

15. The method of claim 1 wherein solid phase material further comprises a silica-based material functionalized with covalently incorporated surface functional groups that serve to disrupt cells and attract nucleic acids selected from hydroxyl, silanol, carboxyl, amino, ammonium, quaternary ammonium and phosphonium salts and ternary sulfonium salts.

16. The method of claim 1 wherein the solid phase material further comprises a polymeric material having covalently incorporated surface functional groups that serve to disrupt cells and attract nucleic acids selected from hydroxyl, silanol, carboxyl, amino, ammonium, quaternary ammonium and phosphonium salts and ternary sulfonium salts

17. The method of claim 13 wherein the nucleic acid binding portion is comprised of a plurality of nucleic acid binding groups selected from carboxyl, NH2, alkylamine, and dialkylamine groups, ternary or quaternary onium groups or mixtures of more than one of these groups.

18. The method of claim 17 wherein the nucleic acid binding portion is comprised of a plurality of nucleic acid binding groups selected from quaternary trialkylammonium, quaternary trialkylphosphonium, quaternary triarylphosphonium, mixed alkyl aryl. quaternary phosphonium groups, and ternary sulfonium groups.

19. The method of claim 13 wherein the nucleic acid binding groups are selected from quaternary trialkylammonium and quaternary trialkylphosphonium groups wherein the alkyl groups each have at least four carbon atoms, and wherein the nucleic acid binding groups cause lysis of cells and viruses to liberate ribonucleic acid.

20. The method of claim 6 wherein the solid phase binding materials comprise nucleic acid binding groups attached to a matrix through a selectively cleavable linkage.

21. The method of claim 1 wherein the acidic solution comprises an aqueous solution having a pH in the range of 1-5.

22. The method of claim 21 wherein the acidic solution comprises an aqueous solution having a pH in the range of 2-4.

23. The method of claim 21 wherein the acidic solution comprises an aqueous solution of an organic or inorganic acid selected from pyridinium salts, mineral acids, monocarboxylic acids, dicarboxylic acids, tricarboxylic acids, and amino acids, as well as their alkali metal, alkaline earth, transition metal, NH4+, quaternary ammonium and quaternary phosphonium salts.

24. The method of claim 2 wherein the reagent for releasing bound ribonucleic acid from the solid phase comprises an alkaline solution having a concentration of alkali of 1 mM to 1 M.

25. The method of claim 1 wherein the solid phase material comprises magnetic particles having a tributylphosphonium nucleic acid binding group linked through a cleavable arylthioester linkage to a magnetic particle matrix.

26. The method of claim 25 wherein the solid phase material has the formula

27. The method of claim 1 wherein the biological sample is selected from bacterial cultures, pelleted cells from bacterial cultures, blood, blood plasma, blood serum, urine sputum, semen, CSF, plant cells, animal cells, and tissue homogenates.

28. A method for extracting ribonucleic acid from a biological sample selected from bacterial cultures, pelleted cells from bacterial cultures, blood, blood plasma, blood serum, urine sputum, semen, CSF, plant cells, animal cells, and tissue homogenates, the sample containing at least one of cells or viruses comprising: a) contacting the sample with an acidic solution having a pH in the range of 1-5 wherein the acidic solution comprises an aqueous solution of an organic or inorganic acid selected from pyridinium salts, mineral acids, monocarboxylic acids, dicarboxylic acids, tricarboxylic acids, and amino acids, and their alkali metal, alkaline earth, zinc, NH4+, quaternary ammonium and quaternary phosphonium salts to form a mixture;b) combining the mixture with a solid phase binding material comprising a matrix portion and a nucleic acid binding portion wherein the solid phase binding material is selected to have the ability to liberate ribonucleic acid directly from biological samples without first performing any preliminary lysis, and wherein no chaotropic agents or detergents are used to effect lysis, and whereby the nucleic acid binding groups cause lysis of cells and viruses to liberate ribonucleic acid; andc) binding ribonucleic acid on the solid phase.

29. The method of claim 28 wherein the solid phase material comprises magnetic particles having a tributylphosphonium nucleic acid binding group linked through a cleavable arylthioester linkage to a magnetic particle matrix.

30. The method of claim 29 wherein the solid phase material has the formula

31. The method of claim 30 further comprising: d) separating the sample from the solid phase having ribonucleic acid bound theretoe) optionally washing the solid phase with at least one wash solution; andf) eluting the bound ribonucleic acid from the solid phase by contacting the solid phase material with a reagent comprising an alkaline solution having a concentration of alkali of 1 mM to 1 M to release the bound RNA into solution.

32. A method for isolating ribonucleic acid from a biological sample selected from bacterial cultures, pelleted cells from bacterial cultures, blood, blood plasma, blood serum, urine sputum, semen, CSF, plant cells, animal cells, and tissue homogenates, the sample containing at least one of cells or viruses comprising: a) contacting the sample with an acidic solution having a pH in the range of 1-5, wherein the acidic solution comprises an aqueous solution of an organic or inorganic acid selected from pyridinium salts, mineral acids, monocarboxylic acids, dicarboxylic acids, tricarboxylic acids, and amino acids, and their alkali metal, alkaline earth, transition metal, NH4+, quaternary ammonium and quaternary phosphonium salts to form a mixture;b) combining the mixture with a solid phase binding material comprising magnetic particles having a tributylphosphonium nucleic acid binding group linked through a cleavable arylthioester linkage to a magnetic particle matrix wherein the solid phase binding material is selected to have the ability to liberate ribonucleic acid directly from biological samples without first performing any preliminary lysis, and wherein no chaotropic agents or detergents are used to effect lysis, and whereby the nucleic acid binding groups cause lysis of cells and viruses to liberate ribonucleic acid; andc) binding ribonucleic acid on the solid phase;d) separating the sample from the solid phase having ribonucleic acid bound thereto;e) optionally washing the solid phase with at least one wash solution; andf) cleaving the selectively cleavable linkage with a cleavage reagent thereby releasing the ribonucleic acid from the solid phase binding material.

33. The method of claim 32 wherein the cleavable linkage is selected from a hydrolytically cleavable group, a disulfide group, a peroxide bond, a group cleavable by an enzyme selected from esterases, hydrolases, proteases, peptidases, and glycosidases, a cleavable 1,2-dioxetane moiety, an electron-rich C—C double bond wherein the double bond is attached to at least one O, S, or N atom, a ketene dithioacetal compound, and a photocleavable linker group selected from nitro-substituted aromatic ethers and esters.

34. The method of claim 33 wherein the hydrolytically cleavable group is selected from carboxylic esters, carboxylic anhydrides, thioesters, carbonate esters, thiocarbonate esters, urethanes, imides, sulfonamides, sulfonimides and sulfonate esters.

35. The method of claim 34 wherein the hydrolytically cleavable linkage is cleaved by reaction with a reagent comprising an alkaline solution having a concentration of alkali of 1 mM to 1 M.